Related Experiment Video
Updated: Oct 2, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What's Now, What's
Andrea Marchetti1, Matteo Rosellini1, Giacomo Nuvola1
1Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, 40138 Bologna, Italy.
Abstract:
In recent years, the advances in the knowledge on the molecular characteristics of prostate cancer is allowing to explore novel treatment scenarios. Furthermore, technological discoveries are widening diagnostic and treatment weapons at the clinician disposal. Among these, great relevance is being gained by PARP inhibitors and radiometabolic approaches. The result is that DNA repair genes need to be altered in a high percentage of patients with metastatic prostate cancer, making these patients optimal candidates for PARP inhibitors. These compounds have already been proved to be active in pretreated patients and are currently being investigated in other settings. Radiometabolic approaches combine specific prostate cancer cell ligands to radioactive particles, thus allowing to deliver cytotoxic radiations in cancer cells. Among these, radium-223 and lutetium-177 have shown promising activity in metastatic pretreated prostate cancer patients and further studies are ongoing to expand the applications of this therapeutic approach. In addition, nuclear medicine techniques also have an important diagnostic role in prostate cancer. Herein, we report the state of the art on the knowledge on PARP inhibitors and radiometabolic approaches in advanced prostate cancer and present ongoing clinical trials that will hopefully expand these two treatment fields.
Insights
New treatments for advanced prostate cancer include PARP inhibitors and radiometabolic therapies. These approaches target DNA repair alterations and cancer cells, offering new hope for patients with metastatic disease.
Area of Science:
- Oncology
- Molecular Biology
- Nuclear Medicine
Background:
- Advances in understanding prostate cancer molecular characteristics enable novel therapeutic strategies.
- Technological innovations are expanding diagnostic and treatment options for clinicians.
- Poly (ADP-ribose) polymerase (PARP) inhibitors and radiometabolic approaches are gaining prominence.
Purpose of the Study:
- To review the current state of knowledge on PARP inhibitors and radiometabolic approaches in advanced prostate cancer.
- To highlight ongoing clinical trials exploring these novel treatment modalities.
- To discuss the potential of these therapies in improving patient outcomes.
Main Methods:
- Review of recent scientific literature on PARP inhibitors and radiometabolic therapies.
- Analysis of the molecular basis for PARP inhibitor efficacy in prostate cancer.
- Examination of radiometabolic agents, including radium-223 and lutetium-177.
- Overview of current and planned clinical trials in advanced prostate cancer.
Main Results:
- Alterations in DNA repair genes are frequent in metastatic prostate cancer, identifying patients suitable for PARP inhibitors.
- PARP inhibitors have demonstrated activity in pretreated patients and are being investigated in various settings.
- Radiometabolic approaches deliver targeted radiation to cancer cells, with radium-223 and lutetium-177 showing promise.
- Nuclear medicine techniques play a crucial diagnostic role in prostate cancer management.
Conclusions:
- PARP inhibitors and radiometabolic approaches represent promising therapeutic avenues for advanced prostate cancer.
- Ongoing clinical trials are expected to further define the role and expand the applications of these treatments.
- Targeting DNA repair pathways and utilizing targeted radiation offer new strategies for managing metastatic prostate cancer.
